GlassScriptPhysician profile
Tilly Lynn Burroughs
NPI 1669109641
$5,753.39
in general payments reported to CMS, 2019-2025
24 companies · $2,266 in 2025
The $2,266 reported for 2025 was more than what 94% of Psychiatric/Mental Health (Nurse Practitioner) providers received nationally (typical 2025 total: $257).
See the full distribution for Psychiatric/Mental Health (Nurse Practitioner)
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2022: $518 · 2023: $1,464 · 2024: $1,506 · 2025: $2,266.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $5,235.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $5,235.37 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Alkermes, INC. | $910.44 | 2023-2025 | Aristada, Lybalvi, Vivitrol |
| Abbvie INC. | $752.04 | 2022-2025 | |
| Janssen Pharmaceuticals, INC | $628.58 | 2022-2025 | Invega Sustenna, Spravato, Invega Trinza |
| Otsuka America Pharmaceutical, INC. | $532.09 | 2022-2025 | Rexulti, Abilify Asimtufii, Abilify Maintena |
| Teva Pharmaceuticals USA, INC. | $437.79 | 2022-2025 | Austedo Xr, Austedo Xr, Uzedy |
| Neurocrine Biosciences, INC. | $434.30 | 2022-2025 | Ingrezza |
| Supernus Pharmaceuticals, INC. | $394.82 | 2024-2025 | Qelbree |
| Axsome Therapeutics, INC. | $390.62 | 2023-2025 | Auvelity |
| Lundbeck LLC | $214.92 | 2023-2025 | Abilify Asimtufii, Rexulti |
| Vanda Pharmaceuticals INC. | $147.72 | 2022-2025 | Fanapt, Hetlioz |
| Takeda Pharmaceuticals U.S.A., INC. | $147.60 | 2022-2025 | Trintellix |
| Corium, LLC | $144.53 | 2023-2025 | Azstarys |
| Iti, INC. (D/B/A Intra-Cellular Therapies, INC.) | $121.77 | 2022-2025 | Caplyta |
| Ironshore Pharmaceuticals INC. | $101.20 | 2022-2024 | Jornay Pm |
| Sunovion Pharmaceuticals INC. | $85.72 | 2022 |
Show all 24 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Bausch Health US, LLC | $85.41 | 2023 | Aplenzin, Wellbutrin |
| Tris Pharma INC | $42.18 | 2024-2025 | Dyanavel Xr |
| Noven Therapeutics, LLC | $41.88 | 2025 | Xelstrym, Secuado |
| E.R. Squibb & Sons, L.L.C. | $35.69 | 2025 | Cobenfy |
| Idorsia Pharmaceuticals US INC | $31.03 | 2023-2024 | Quviviq |
| Sage Therapeutics, LLC | $21.88 | 2025 | Zurzuvae |
| Neos Therapeutics, LP | $19.03 | 2025 | Adzenys Xr-Odt |
| Novo Nordisk INC | $17.54 | 2023 | Rybelsus, Ozempic |
| Collegium Pharmaceutical, INC. | $14.61 | 2025 | Jornay Pm |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Tilly Burroughs listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.